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Abstract 
Alzheimer’s disease (AD) is the main cause of dementia, a disease characterized by an 
impairment in memory, language, and cognition. It is estimated to affect around 46 million people 
worldwide. The economic costs of AD will soon be unbearable. Therefore, efforts to find a 
treatment to halt or even slow the progression of the disease have become a priority for the 
scientific community. The symptoms of AD are cognitive impairment and progressive 
neurodegeneration. At the cellular level, the abnormal deposition of amyloid-b (Ab) species is 
thought to be the trigger of the disease, although there are cellular stressors that also play a role 
in the progression of AD. b-site amyloid precursor protein cleaving enzyme 1 (BACE1) is 
responsible for 80% of Ab production in the brain. Hence, strategies such as small molecules 
inhibitors or antibodies targeting BACE1 have been generated. However, limitations such as 
cross-reactivity with BACE2 and poor blood-brain-barrier (BBB) crossing respectively, have 
limited their success. In this context, gene therapy has emerged as an alternative approach for the 
treatment of neurodegenerative diseases like AD. Therapies for central nervous system (CNS) 
based on the use of adeno-associated virus (AAV) are being widely developed, as they have the 
advantages of providing a higher specificity to the target, being safe, infect several cells types and 
provide long-term expression of any given therapeutic transgene. Thus, strategies such as passive 
immunization by AAV-mediated delivery of antibody-encoding genes (vectored 
immunoprophylaxis: VIP) may be an ideal alternative to treat not only AD, but also a wide 
spectrum of neurodegenerative disorders. Here, a novel AAV-based therapeutic strategy is 
evaluated, aiming to deliver an anti-BACE1 nanobody that efficiently decreases the levels of Ab 
in the CNS after systemic delivery. Therefore, we validated the expression of the nanobody in 
three AD mouse strains: APPDutch, APPNL-G-F and APP/PS1. The activity of the nanobody was 
evaluated indirectly by measuring Ab content in tissue extracts. A significant reduction in Ab 
was observed in APPDutch and APPNL-G-F. However, the Ab content did not change in the APP/PS1 
strain, most probably due to the severity of amyloidosis, characteristic of this model. In this thesis, 
we attempted an optimization of the AAV vector to boost the nanobody transgene expression by 
using a self-complementary (sc) AAV conformation. 
 
Keywords: AAV vector, gene therapy, Alzheimer’s disease, vectored immunoprophylaxis, 
nanobody  
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Resumo 
Atualmente, a Doença de Alzheimer é a principal causa de demência, afetando mundialmente 
cerca de 46 milhões de pessoas. A incessante procura de uma cura para o Alzheimer, de terapias 
que impeçam a propagação da doença ou até mesmo de biomarcadores para o diagnóstico 
prematuro da doença, está longe de acabar. No entanto, os custos relacionados com esta doença 
serão incomportáveis nas próximas gerações. Em 1906, Alois Alzheimer descreveu pela primeira 
vez uma doença que numa fase celular foi caracterizada pela formação de emaranhados 
neurofibrilhares e pela deposição de placas amilóides no cérebro, posteriormente ocorre perda 
neuronal, distrofia dos astrócitos e neurónios e alterações vasculares, nesta fase, os pacientes 
apresentam declínio cognitivo e por fim demência. A maioria dos casos de Alzheimer são 
esporádicos e surgem em pacientes com idade avançada. No entanto, existem casos hereditários 
e de early onset, que ocorrem devido a mutações em genes que codificam para as presinilinas 
(PSEN) e para a amyloid precursor protein (APP), proteínas que estão envolvidas na via 
amiloidogénica, e que favorecem a formação das espécies de amilóide-b (Ab) tóxicas. A hipótese 
de cascata amiloidogénica propõe que as placas amilóide, os péptidos Ab que as constituem, e o 
seu metabolismo, têm um papel fundamental no desenvolvimento da doença de Alzheimer. 
Consequentemente, mutações nas PSEN e em APP, enzima e substrato da via amiloidogénica, 
são causadoras da doença, e são frequentemente manipuladas para criar modelos de Alzheimer in 
vitro e in vivo. O modelo de cascata amiloidogénica, por ter apenas em conta o papel da deposição 
das placas amilóides ao nível dos neurónios, exclui outros elementos, como a neuroinflamação e 
a disrupção da barreira hemato-encefálica (BBB), que também apresentam uma função 
fundamental no desenvolvimento do Alzheimer. 
 
A enzima BACE1 (b-site amyloid precursor protein cleaving enzyme 1) é a responsável pelo 
processamento da APP pela via amiloidogénica, deste modo, tem sido um dos principais alvos de 
investigação para terapias de Alzheimer. Inibidores de BACE1 têm sido um êxito em estudos in 
vitro, sendo que muitas moléculas com potencial terâpeutico avançarem para ensaios clínicos, no 
entanto a maioria dos ensaios não foram bem sucedidos e foram posteriormente descontinuados. 
Uma alternativa às moléculas inibidoras de BACE1 é, então, a administração de anticorpos anti-
BACE1, que por serem mais estáveis e apresentarem uma maior especificidade ao substrato, tem 
um elevado interesse terâpeutico. No entanto, até estas moléculas apresentam desvantagens, tais 
como ineficiência em atravessar a BBB e um tempo de vida curto. O desenvolvimento de terapia 
génica baseada em vetores virais permite o transporte de genes de que codificam para anticorpos, 
ultrapassando as desvantagens dos anticorpos. 
 
Recentemente, a terapia génica baseada em vetores virais emergiu como um método eficiente de 
expressão de genes com potencial terâpeutico, através de técnicas moleculares. Este método, 
dependendo da origem do vetor, tem duas subdivisões. A terapia génica não viral, que consiste 
na administração de moléculas de origem não viral, tal como polimeros catiónicos, lípidos 
catiónicos, entre outros. Estes métodos apesar de baratos, não são eficientes para o tratamento de 
doenças do sistema nervoso central (CNS). Por outro lado existe a terapia génica viral , em que 
variados tipos de vetores têm sido desenvolvidos, sendo os mais estudados os adenovírus, 
lentivírus e vírus adeno-associados (AAV), sendo este último mais eficientes. AAV são vírus não 
replicativos e não patógénicos, que contêm um genoma de 4,7 kb de DNA de cadeia simples. Os 
vetores AAV não integram o genoma, e são produzidos através da remoção dos genes virais que 
são flanqueados pelas duas regiões terminais invertidas (ITR), sendo posteriormente substituídos 
por uma cassete de expressão génica que contém o gene de interesse. Existem 11 serótipos 
naturais e cerca de 100 variações destes, sendo este determinado pela sequência de amino-ácidos 
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da cápside, sendo que o tropismo de cada serótipo depende da cápside. O serótipo 9 e o serótipo 
PHP.B, uma variação do serótipo 9, apresentam uma grande afinidade para células do sistema 
nervoso, sendo que o último é bastante eficiente a atravessar a BBB e a transduzir células 
nervosas.  O genoma destes vetores pode adquirir duas conformações, uma de cadeia simples (ss), 
outra de cadeia complementar (sc), a segunda é formada devido a uma mutação em um dos ITR, 
que confere à molécula de DNA uma conformação de cadeia dupla, pronta a ser transcrita pela 
maquinaria da célula hospedeira, sendo que ambos permitem uma expressão contínua do 
transgene. A conformação sc permite uma expressão do transgene mais rápida e mais eficiente, 
apesar a capacidade de transporte do vetor diminuir para 2,5 kb. O desenvolvimento e otimização 
destes mecanismos permitem ao vetor atravessar a BBB, eficientemente transduzir neurónios e 
aumentar a expressão de moléculas terapêuticas, tais como anticorpos ou nanoanticorpos 
altamentes eficientes. Esta técnica é chamada de vectored immunoprophylaxis (VIP). 
 
VIP consiste na imunização passiva de anticorpos através de terapia génica baseada em vírus, 
sendo que as células transduzidas expressam o anticorpo codificado no transgene, estas proteínas 
tem uma expressão endógena e continuada, permitindo que apenas uma administração do vetor 
tenha um efeito prolongado. Os anticorpos monoclonais, apesar de apresentarem resultados 
positivos, tem-se provado ineficientes após administração de vetores que contêm a sua 
informação génetica no genoma, contrariamente aos nanoanticorpos. Os nanoanticorpos são 
produzidos por camelídeos e são pequenas moléculas com alta estabilidade, baixa 
imugenogeneicidade e alta afinidade para pequenos antigénios. Os nanoanticorpos, devido ao seu 
tamanho, são facilmente introduzidos no genoma de um vetor scAAV, que apresenta uma 
conformação que aumenta a expressão do transgene contido no seu genoma.  
 
Este trabalho focou-se no desenvolvimento de uma nova terapia VIP baseada em vírus AAV. O 
vetor administrado continha no seu genoma o transgene que codifica para um nanoanticorpo com 
atividade anti-BACE1 (B9), anteriormente validado in vitro. Após administração do vetor que 
continha o gene que codifica para o nanoanticorpo B9, a diminuição do conteúdo Ab foi detetável 
em duas das três estirpes em estudo, APPDutch e APPNL-G-F, no entanto não foi detetável a alteração 
nos níveis de Ab na estirpe APP/PS1, possivelmente devido à agressividade do modelo na 
deposição das espécies Ab. A optimização do vetor é fundamental para aumentar a expressão do 
transgene e para aumentar o efeito terâpeutico do nanoanticorpo de modo a que haja uma 
diminuição dos niveís de Ab. Deste modo, avaliou-se a eficiência de um vetor com uma 
conformação scAAV, sendo expectável que aumente a expressão do transgene. Os conteúdos de 
Ab entre os grupos injetados com ssAAV e o scAAV permaneceram semelhantes aos do grupo 
injetado com o vetor controlo, possivelmente devido à baixa concentração de Ab nos cérebros 
dos ratos APPDutch na idade analisada. Posteriormente, a expressão do nanoanticorpo após injeção 
com as duas conformações, ssAVV e scAAV, foi comparada. No entanto e contrariamente ao 
expectável, a conformação ssAAV conferiu uma expressão mais acentuada do que a conformação 
scAAV, deste modo concluimos que os benefícios que advêm a conformação sc não compensam 
a perda dos elementos regulatórios presentes no vetor com a conformação ss.  
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A administração de vetores capazes de transportar um nanoanticorpo com efeitos terapêuticos é 
de elevado interesse não só para tratamento do Alzheimer mas também para o tratamento de 
outras doenças do CNS. A administração de B9 por via de um AAV vector, ainda precisa de 
otimização, no entanto apresenta um grande potencial terapêutico. 
 
Palavras-chave: vetor AAV, terapia génica, doença de Alzheimer, vectored immunoprophylaxis, 
nanoanticorpo 
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1 Introduction 
 
1.1 Alzheimer’s disease 
 
Alois Alzheimer described in 1906 “a peculiar severe disease process of the cerebral cortex”, a 
disease that was later described by the deposition of neuronal tangles and amyloid plaques in the 
brain, associated with astrocytic and neuronal dystrophy, neuronal loss and vascular alterations 
(Hippius and Neundörfer, 2003; De Strooper and Karran, 2016). The German psychiatrist 
described the pathology in the patient August Deter (Jarvik and Greenson, 1987), whose 
symptoms included progressive memory loss, cognitive and functional impairment, and 
psychiatric disturbances.  
 
1.1.1 Global Impact of Dementia and Alzheimer’s 
Nowadays this disease, known as Alzheimer’s disease (AD), is the most common cause of 
dementia. It is estimated that 47 million people worldwide are diagnosed with dementia, 
representing a socioeconomic burden for society, which will be unbearable in the next generations 
(Picanco, et al., 2018; Prince et al., 2016; Saito and Saido, 2018). By 2030, it is estimated that 
the total cost of this disease will reach 2 trillion USD dollars. By 2050, 68% of dementia cases 
are expected to occur in low to middle income countries (Prince et al., 2015). 
 
AD neuropathology is hypothesized to begin before appearance of mild cognitive impairment and 
dementia state (Heneka et al., 2015). At the cellular level, an accumulation of extracellular 
amyloid-b (Ab) plaques occurs, together with an intracellular accumulation of 
hyperphosphorylated tau protein, which forms neurofibrillary tangles (NFT) (Sakakibara et al., 
2018; Braak and Braak, 1991; Hyman et al, 2012; Serrano-Pozo et al., 2011). These molecular 
processes are accompanied by astrocytic and microglial activation (Jankowsky and Zheng, 2017). 
Amyloid plaques and NFT are considered the pathological hallmarks of AD. They begin to appear 
in the cortex, 25-30 years (for the plaques) and 15 years (for the NFT) before the symptoms of 
AD start to appear (Saito and Saido, 2018; Selkoe and Hardy, 2016; Bateman et al., 2012). 
 
Currently, there are no effective therapies for established AD, or even treatments which slow 
disease progression. There is also a lack of validated biomarkers hampering early diagnosis of 
AD (Peng et al., 2016; Heppner et al, 2015). However, there are therapies available that delay the 
appearance or the progression of the symptoms, providing symptomatic relief (Wisniewski et al., 
2012; Kumar et al., 2014).  In early stages of the disease prevention therapies, such as the 
administration of the Aβ-specific vaccine	CAD106	were	unsuccessfully	attempted (Karran et al, 
2011). Moreover, there are also symptomatic therapies such as cholinesterase inhibitors and N-
methyl-D-aspartate (NMDA) receptor antagonist-memantine (Ferreira-Vieira et al. 2016, 
Omerovic et al., 2008). The basis for the cholinesterase inhibitors therapies is acting on delaying 
the breakdown of acetylcholine (Ach) since AD brains show defects in cholinergic transmission. 
Memantine acts on the excitotoxicity caused by glutamate, which is one of the consequences of 
AD (Lewerenz and Maher, 2015). Although the current alternatives for AD patients may delay 
the progression of the symptoms (Omerovic et al., 2008) and provide symptomatic relief, a 
therapy that halts the progression of the disease at a mechanistic level is still needed. 
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The majority of AD cases are late onset and sporadic, with no evident Mendelian pattern, with 
the risk of disease increasing with life expectancy (Heppner et al., 2015; Querfurth and Laferla, 
2010). These cases are due to a network of environmental, genetic and lifestyle factors (Lahiri et 
al, 2004). However, there is a small percentage of AD cases with a hereditary pattern caused by 
specific established mutations, known as familial Alzheimer’s disease (FAD) (De Strooper and 
Karran, 2016). These mutations are present in genes such as presenilin (PSEN1, PSEN2) and 
amyloid precursor protein (APP), which is a type I transmembrane expressed in the brain. These 
genes take part in the amyloidogenic pathway, and when mutated, APP is cleaved in a manner 
that favors formation of Ab42 (Jankowsky and Zheng, 2017), a toxic species which is known to 
aggregate and initiate the disease. Mutations in PSEN1 and PSEN2 are the most common 
mutations identified in FAD (Veugelen et al., 2016). PSEN provides the catalytic core to g-
secretase, which participates in the processing of APP (Veugelen et al., 2016; Matsumura et al., 
2014; De Strooper et al., 1998; Wolfe et al., 1999). Furthermore, there are reports including other 
genetic risk factors for sporadic forms of AD, such as point mutations in a receptor expressed on 
myeloid cells 2 (TREM), and the presence of the allele of ApoliproteinE e4 (Jankowsky and 
Zheng, 2017). 
 
1.1.2 Amyloid Cascade Hypothesis 
The amyloid cascade hypothesis, a neuron-centric model, proposes that amyloid plaques, their 
constituent Ab peptides, and disturbances in Ab metabolism, play a central role in AD (De 
Strooper and Karran, 2016).  
 
The basis for the amyloid cascade hypothesis lies in the production of Ab through the cleavage 
of APP by b- and g-secretases. There are two pathways of cleavage of APP: the non-
amyloidogenic and the amyloidogenic one (Fig. 1). In the non-amyloidogenic pathway, APP is 
processed by a-secretases and g-secretases, producing a sAPPa ectodomain, a p3 fragment, and 
an amyloid precursor protein intracellular domain (AICD). sAPPa is thought to have functions 
like neurotransmission and synaptic plasticity among others (Wang et al., 2014; Seabrook et al., 
1999; Yang et al., 2009; Mockett et al., 2017; Muller et al. 2017). The AICD has a role in 
regulating transcription (Kimberly et al.,2001; Cupers et al., 2001), meanwhile, the p3 fragment 
is also found in amyloid plaques. The amyloidogenic pathway aforementioned is initiated by 
activity of the β-secretase and continued by g-secretases. This pathway produces sAPPb, AICD 
and Ab peptides. Ab peptides are known to be prone to aggregate and form soluble oligomers, 
that turn into protofibrils, this species maturse and forms fibrils, which aggregate and deposit in 
the form of senile plaques (Kumar et al., 2015).  
 
The b-site amyloid precursor protein cleaving enzyme 1 (BACE1), a b-secretase, is a type I 
transmembrane protein that processes the amyloidogenic pathway. BACE1 is an aspartyl protease 
from the peptidase A1 family (Vassar et al.,1999), commonly expressed in the brain, especially 
in neurons. This enzyme became the main target for AD therapy since it was discovered in 1999 
due to its key role in the amyloid cascade hypothesis, since it is responsible for 80% of all Ab 
production (Read and Suphioglu, 2013). 
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Figure 1. Amyloid precursor protein (APP) processing pathways (Graphic adapted from Zhao et al., 2016) 
 
The Ab species found in AD and normal brains are disparate. In normal brains, the most abundant 
species is Ab40. Meanwhile, in AD brains, Ab42 and longer species are the most prevalent. This 
difference is, in part, due to g-secretases that cleave fragments of different sizes (Portelius et al., 
2010; Chavez-Gutierrez et al., 2012). Moreover, Ab42 oligomers are responsible for inducing 
oxidative stress and tau hyperphosphorylation, which cause toxic effects and neuronal 
degeneration (Kumar et al., 2015).  
 
However, this model lacks the inclusion of the role of other cellular players, does not take into 
account interactions between the different cell types, and the progression of the disease, nor does 
it explain the asymptomatic period of AD (De Strooper and Karran, 2016). The amyloid cascade 
hypothesis, being a quantitative model (higher concentration of Ab, means higher concentration 
of plaques, and consequently progression of AD), does not provide an explanation for the 
qualitative aspects. For instances, mutations in PSEN cause a disruption in the cleavage of Ab, 
generating species longer than Ab40, which are more prone to aggregate and deposit in plaques 
(De Strooper and Karran, 2016; Chavez-Gutierrez et al., 2012; Szaruga et al., 2015; Saito et al., 
2011). 
 
1.1.3 AD-Related Stressors 
Additional stressors involved in AD development include neuroinflammation, vascular 
modifications among others (De Strooper and Karran, 2016). Neuroinflammation is a protective 
mechanism, mediated by microglia, astrocytes, neurons, T-cells and other mediators (Kempuraj 
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et al., 2017). Initial inflammatory responses are thought to preserve homeostasis in the central 
nervous system (CNS), partially restoring the damaged glial cells and neurons. Once the 
responses become chronic and inhibit the neuronal regeneration, inflammation favors disease 
progression independently from the deposition of the plaques and the NFT, becoming irreversible 
and pathological (De Strooper and Karran, 2016; Kempuraj et al., 2017).  
 
The integrity of the blood-brain barrier (BBB) also plays an important function, due to its role in 
the clearance of Ab (De Strooper and Karran, 2016). The BBB is constituted by astroglial end-
feet, endothelial cells and pericytes and smooth muscle cells. Gap junctions in the BBB allow the 
passage and elimination of Ab and tau. Defects in this mechanism may lead to 
neuroinflammation, vascular and synaptic dysfunction, which may lead to the progression of AD 
(De Strooper and Karran, 2016). 
 
1.1.4 BACE1 as a potential therapeutic target for AD 
According to the amyloid cascade hypothesis, lowering levels of Ab levels would be sufficient to 
halt the progression of the disease, although a complicating factor may be the differences in 
propensity to aggregate between Ab species (De Strooper and Karran, 2016). The findings that 
BACE1 acts on the first and rate-limiting step in Ab generation in the brain, and that the loss of 
b-secretase activity in knock-out mouse models showed a reduction in b-amyloid peptide 
production, clearly indicate that BACE1 is an excellent therapeutic target for the treatment of AD 
(Luo et al., 2001; Roberds et al., 2001). The defects shown in the knock-out mice were mainly 
related to BACE1 inhibition during developmental stages and are due to other substrates of 
BACE1 and not APP (Barão et al, 2016), meaning that the current therapies should be safe since 
they are administered in adults (Roberds et al., 2001). There are small molecules used for 
inhibition of BACE1 that reached phase 2/3 clinical trials, which are shown to be safe, but overall, 
they were ineffective and were discontinued, possibly due to some factors, such as solubility, 
bioavailability, and potency among others (Read and Suphioglu, 2013). For instances, the 
promising Merck’s Verubecestat administered to patients with mild-to-moderate AD was 
discontinued in 2017 due to “virtually no chance of finding a positive clinical effect (Hawkes, 
2017). In July 2019, the Amgen/Novartis’ Umibecestat (CNP520) was also discontinued due to 
worsening of the symptoms. In September 2019, the promising Eisei/Biogen’s Elenbecestat was 
also discontinued, due to a finding of unfavorable risk/benefit (NCT02956486). 
 
Additionally, some BACE1 inhibitors show an additional problem, cross-reactivity with BACE2, 
also a b-secretase with around 49% homology with BACE1. Although BACE2 is expressed 
mainly in colon, kidneys, and pancreas (Yan et al., 2017; Read and Suphioglu, 2013), this cross-
reactivity could increase the risk of off-target toxicity. For instances, BACE2 also processes the 
pigment cell-specific melanocyte protein, that is one of the responsible proteins for the formation 
of the melanosome complex in pigment cells (Rochin et al., 2013). Hence, BACE 2 inhibition 
results in hypopigmentation, which indeed is the most consistent phenotype in pre-clinical studies 
where BACE1/2 are inhibited, a clear sign of cross-reactivity (Dominguez et al., 2005; Shimshek 
et al., 2016). Unfortunately, most of the compounds that reached a clinical trial level have shown 
some degree of cross-reactivity (Farzan et al., 2000; Shimshek et al., 2016). 
 
An alternative to small molecules inhibitors is the administration of antibody-based therapies. 
Antibodies are more stable and more target specific compared to the BACE1 inhibitors in study. 
However, these molecules also present some drawbacks, for instances after systemically delivery 
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of the antibody, only a small fraction of it crosses the BBB. Moreover, a direct intracerebral 
injection of an anti-BACE1 antibody proved to be efficient in the hippocampus of APPDutch mice, 
although this invasive strategy is not ideal for translational purposes. (Zhou et al., 2011). Many 
strategies were developed to surpass this limitation, such as ultrasonic opening of the BBB, among 
others (Jordão et al., 2010), however they all showed perturbation of brain homeostasis and low 
efficiency. Currently, gene therapy using viral vectors is being to deliver transgenes that encode 
therapeutic proteins, such as anti-BACE1 antibodies. 
 
1.2 Gene therapy as therapeutic approach for CNS diseases 
Gene therapy has become a hot topic in the past few years. The Human Genome Project and the 
identification of genes underlaying Mendelian disorders created the concept that DNA can be 
manipulated as a clinical therapy (Kotterman et al., 2015; Rommens et al., 1989; Riordan et al., 
1989; Kerem et al., 1989; MacDonald et al., 1993). Therefore, gene therapy has the potential to 
treat diseases by manipulating genes to silence (faulty) gene expression, to restore gene function, 
or to insert an exogeneous therapeutic transgene (Cox et al., 2015; Kay, 2011; Vaishnaw et al., 
2010; Foldvari et al, 2016). The complexity of cells and tissues poses a barrier to efficiency of 
gene transfer. In therapies for CNS disorders, the BBB is also a limitng factor. Therefore, the 
success in any therapy will rely on the efficiency of the delivery system in crossing the BBB and 
delivering a DNA cargo after systemic administration (Jayant et al., 2016; Upadyay, 2014; Misra 
et al., 2003; Timbie et al., 2015; Bourdenx et al., 2014; Jayant and Nair, 2016). 
 
Gene therapies have been developed over the past two decades focused in monogenic and 
recessive disorders. Specifically, been the basis for successful therapies involving the 
hematopoietic system (Naldini et al. 2015; Cox et al., 2015; Gaspar et al., 2011; Howe et al., 
2008; Aiuti et al., 2013). These diseases have a known molecular background, such as hereditary 
diseases, cancer, and chronic infections (Naldini et al. 2015). Phase I/II clinical trials on 
thalassemia, hemophilia and retinal dystrophy are some of the diseases where gene therapy has 
proven efficacious and safe (Naldini et al. 2015). An optimized vector must have the following 
characteristics: (i) protection of the DNA cargo from degradation until its internalization in the 
nuclei of cells (ii) effectiveness; (iii) specificity for a given substrate; (iv) long-term expression; 
(v) low immune response; (vi) safety; (vii) accessibility; (viii) low cost (Jayant et al., 2016).  
 
Depending of the origin of the vector, gene therapy is branched in two main sub-categories – non- 
viral and viral gene therapy.  
 
1.2.1 Non-viral gene therapy 
Non-viral gene therapy consists of molecules that can transfer a gene into a cell (Jayant et al., 
2016). The most common methods are cationic polymers, cationic lipids, engineered polymers, 
nanoparticles, and naked DNA (Jayant et al., 2016; Ramamoorth and Narvekar, 2015). These 
molecules form complexes or nanoparticles that involve the nucleic acids (Foldvari et al, 2016). 
 
Non-viral methods are more efficient in localized, non-invasive therapies, for instance 
dermatological, pulmonary or mucosal targets, since they are more accessible and easy to target 
(Foldvari et al., 2016). These methods are safer and cost-effective, compared to viral vector-based 
gene therapy (Foldvari et al., 2016). The main disadvantages of these therapies are the short-term 
expression, and the fact that these therapies showed less efficiency in gene delivering compared 
to viral gene methods (Foldvari et al, 2016; Jayant et al., 2016). 
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1.2.2 Virus-based gene therapy 
In early stages of gene therapy, mammalian virus-based vectors proved to be an efficient vehicle 
to carry genes of interest (Kotterman et al., 2015). The pathogenicity of a virus can be removed, 
by the elimination of viral genes, retaining the capacity and efficiency of gene transfer carrying a 
therapeutic gene, originating a viral vector (Naso et al, 2017; Robbins and Ghivizzani, 1998). In 
1999, during a clinical trial using adenovirus (Ad) to treat ornithine transcarbamilase defiency, a 
patient died due to systemic inflammation and organ failure, leaving gene therapy in a hiatus 
(Kotterman et al., 2015). However, with modern technologies and recent research, viral gene 
therapy returned to the spotlight. 
 
Nowadays, viral gene therapy is widely used, due to the success as viral vectors of lentivirus and 
adeno-associated virus (AAV) (Kotterman et al., 2015; Jayant et al., 2016). The latter is 
considered to be the safest option since it is a non-pathogenic virus (Jayant et al., 2016; Samulski 
and Muzyczka, 2014). These vectors have a high efficiency of transduction and are proved to 
have long-term expression, being more efficient than non-viral vectors (Jayant et al., 2016; 
Bouard et al., 2009).  
 
The life cycle of a wild-type virus starts with infection of the host cell, followed by the replication 
of the viral genome, capsid production, packaging of the viral genome, and ending with the lysis 
of the cell and releasing of the viral particles (Samulski and Muzyczka, 2014; Bourdenx et al., 
2014; Naso et al., 2017). The viral vectors take advantage of the wild-type lifecycle and are 
engineered by removing the viral genes and retaining the packaging signals (Kotterman et al., 
2015). The viral genes that encode for replication and structure are provided in trans, generating 
mechanisms to deliver the gene of interest without the pathogenicity, the viruses can then be used 
as vectors for therapeutic ends (Choudhury et al., 2017).  
 
Currently, there are several viral vector types developed and with therapeutic interests (Table 1). 
In the following sections the major vectors types are briefly discussed. 
 
Table 1. Viral vectors for gene therapy (adapted from Choudhury et al.,2017) 
 Adenovirus Lentivirus AAV Retrovirus Herpes 
Simplex Virus 
Packaging 
capacity 
36 kb 7-9 kb 4.5 kb 7-8 kb 50-150kb 
Genome dsDNA ssRNA ssDNA ssRNA dsDNA 
Coat Naked Enveloped Naked Enveloped Enveloped 
Transgene 
expression 
Transient 
expression 
Long term 
expression 
Long term 
expression 
Long term 
expression 
Long term 
expression 
Genome 
integration  
Non 
integrative 
Integrative Non 
integrative 
Integrative Integrative and 
non-integrative 
Tropism Dividing 
and non-
dividing 
cells 
Dividing 
and non-
dividing 
cells 
Dividing 
and non-
dividing 
cells 
Dividing 
cells 
Dividing and 
non-dividing 
cells 
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1.2.2.1 Adenovirus 
These viruses belong to the Adenoviridae family and present a non-enveloped double stranded 
DNA genome. Ad enters the cells by endocytosis, but the virus developed a strategy to avoid the 
lysosome/endosome compartment. Ad vectors have a large packaging capacity, and are capable 
of carrying a 36 kb transgene. These vectors do not integrate in the genome and when injected in 
the parenchyma of a tissue are able to scatter and transduce broad number of cells. The drawback 
of Ad vectors is that the innate immune response is severe, leading to inflammation and 
cytotoxicity, since the organism can present pre-existing immunity. Ad vectors are normally used 
in cancer trials. Concerning CNS disorders, it has been used principally research on for brain 
tumor therapies. Ad vectors are also used for vaccination, by taking advantage of the immune 
response generated (Choudhury et al., 2017; Jooss and Chirmule, 2003; Crystal, 2014). 
 
1.2.2.2 Lentivirus  
Lentivirus are members of the Retroviridae family, derived from human immunodeficiency 
viruses (HIV). Lentiviral vectors (LV) are able to transfect both dividing and non-dividing cells, 
entering the cell by fusion of the envelope with the plasma membrane,delivering its contents into 
the cytoplasm, followeb by a release of the genome from the capsid, and integrating the transgene 
in the host cell genome (Choudhury et al., 2017). The packaging capacity of the vector is up to 
8,5 kb. LV are capable of long-term expression, and since it integrates the genome, the therapeutic 
transgene is inherited by the progeny. The drawbacks of LV are its large size that prevents a wide 
biodistribution of the vector, and the immune innate responses by the host organism, although 
improvements in these vectors were made to increase the safety of the vector (Choudhury et al., 
2017; Escors and Breckport., 2015), for example the development of non-integrating lentiviral 
(NIL) vectors, that persists in an episome, decreasing the risk of mutation caused by integration 
of the viral genome. LV are the second most common vector for gene delivery in the CNS, mainly 
in AD and Parkinson’s disease (Lentz et al., 2012). 
 
1.2.2.3 Retrovirus and Herpes Simplex Virus 
Retrovirus and Herpes Simplex Virus (HSV) are also vectors used in gene therapy, although their 
usage is less frequent. Retrovirus are derived from Moloney murine leukemia virus. This virus is 
not able to transfect non-dividing cells, compromising its use to treat CNS-related disorders. 
Instead, they are normally used for lineage determination in embryos (Choudhury et al., 2017). 
Retrovirus-based vectors show similarities with LV regarding packaging capacity and 
transfection mechanism, but the production of this virus has lower titers. HSV vectors are able to 
transfect neurons among other cell types and are able to either integrate into the genome of the 
host cell, or to as persist as episomes. The interesting characteristics of these vectors are that they 
can deliver a transgene up 150 kb in size and are produced with a high titer. Moreover, this vector 
is able to transduce neurons among other cell types. Currently, there is no clinical study using 
these vectors, due to problems with toxicity and production. (Choudhury et al., 2017; Lentz et al., 
2012). 
 
1.2.3 Adeno-Associated Virus 
AAV are non-pathogenic and non-replicative viruses, belonging to the Parvoviridae family 
(Rincon et al., 2018; Kotterman et al., 2015). In fact, AAVs are dependent on other viruses to 
replicate. Wild-type AAV carries a 4,7 kb single stranded DNA genome. It is a non-enveloped 
virus, similar to Ad, and possesses an icosahedral capsid. The genome of wild-type AAV is 
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constituted of 3 open-reading frames (ORF), flanked by 2 inverted terminal repeats (ITR). ITRs 
function as an origin site of replication and as a signal for encapsidation. The rep ORF, 
responsible for viral replication signals, encodes 4 non-structural proteins, and has further 
functions regulating viral transcription, genome integration, and virion assembly. The cap ORF 
encodes 3 structural proteins that constitute the virus 60-mer capsid (VP1-3). The third ORF is 
within the cap ORF; it encodes the assembly-activating protein, whose function is to localize the 
individual capsid proteins and assemble then into the final capsid structure (Kotterman et al., 
2015). 
 
Recombinant AAV vectors do not integrate the host genome (Naso et al., 2017). In AAV vectors, 
the viral genes are removed and are replaced by an expression cassette containing the transgene 
flanked by the ITR (Kotterman et al., 2015). To produce AAV vectors, the viral genes are 
provided in trans as well as the helper viral genes provided by adeno or herpesvirus (Kotterman 
et al., 2015; Flotte, 2004; Naso et al., 2017). AAV vectors give stable transgene expression, even 
in the absence of helper viral genes. AAV vectors are capable of transfecting dividing cells as 
well as non-dividing cells, such as neurons, persisting in the host cell as concatemers in stable 
episomes (in the absence of Rep), which makes them an interesting tool for CNS-related disorders 
(Choudhury et al., 2017; Kotterman et al., 2015). Although AAV vectors are less immunogenic 
than other vectors, such as LV, they might cause a mild innate immune response, due to the capsid 
or the transgene, blocking the therapeutic activity of the vector (Kotterman et al., 2015). 
 
Currently, there are 11 naturally occurring AAV serotypes and over 100 different variants of these 
serotypes described (Kotterman et al., 2015). An AAV serotype is determined by the amino acid 
sequence of VP1-3. The tropism, or the ability to transduce more efficiently a given tissue or cell 
type, depends highly on the capsid (Dodiya et al., 2015; Jonquieres et al., 2019). The ITR derived 
from the AAV2 serotype is the most commonly used as a genome template, since it was the first 
serotype identified (Naso et al., 2017). Meanwhile, AAV serotype 9 (AAV9), unlike any other 
naturally occurring serotype, is able to cross the BBB and transfect the heterogeneous cells 
present in the brain after intravenous injection. Therefore it is one of the preferred serotypes used 
for CNS-directed gene therapy (Lykken et al, 2018). 
 
In an attempt to optimize AAV9, Deverman and colleagues developed a strategy to effectively 
screen new capsids generated by inserting in AAV9 7 amino acids of randomized sequence 
between the amino acids 588 and 589, which are encoded in the cap gene. The capsids were 
produced by using the CRE-recombination based AAV target evolution method (CREATE) 
(Deverman et al., 2016). The most enriched capsid, the PHP.B, encodes the amino acid sequence 
TLAVPFK (Deverman et al., 2016). It was proved PHP.B provided a higher efficiency in gene 
transfer due to an improved capacity to efficiently cross the BBB, increasing the bioavailability 
of the vector in the CNS improving the final transduction levels without significant off-target 
effects, after systemic injection (Rincon et al., 2018; Deverman et al., 2016).  
 
AAV genome replication depends entirely on the resolution of the hairpins formed in the ITRs. 
A complex of replication, containing the host polymerase binds to one of the ITRs. On the other 
ITR, an endonuclease Rep nicks the ITR at the terminal resolution site, followed by the elongation 
of the molecule by the replication complex, replicating a single-stranded (ss). The ssAAV 
conformations needs to be converted in a double-stranded conformation in order to start the 
transcription, which is a limiting step of the gene expression, since some cell types have a limited 
ability to synthesize a double stranded DNA from a single stranded genome (McCarty et al., 2008; 
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Rincon et al., 2018).The self-complementary (sc) conformation can overcome this limiting step, 
providing an increased efficiency and increased speed of transgene expression. The sc 
conformation is formed when Rep fails to nick the terminal resolution site, due to the deletion of 
this sequence in one of the ITR. The replication complex reaches the mutated terminal resolution 
site and continues to elongate through the ITR and copies towards the initial ITR. After the initial 
replication cycle, the end product is a DNA molecule with 2 wild-type ITRs at the ends, and a 
mutated ITR in the middle of the molecule. The single stranded DNA molecule has two regions 
that self-complement, therefore the molecule can fold and form a double stranded molecule 
(McCarty et al., 2008). Typically, the wild-type AAV genome is packaged in an ssDNA 
conformation. After uncoating, the genome anneals and forms a double-stranded DNA molecule. 
Therefore, in order for the scAAV conformation to be packaged with a single stranded genome, 
the effective size has to be reduced to 2500 bp, or 2200 bp for the transgene and about 145 bp for 
the ITR.  
 
An ideal vector must provide long-term correction of the disorder with one single, non-invasive 
treatment (Lykken et al, 2018). Additionally, with systemic delivery systems for CNS-directed 
targets there are increased difficulties compared to other targeted therapies, such as the liver and 
heart (Deverman et al., 2016). In CNS-targeted therapies, to reach a therapeutic effect, a large 
and heterogeneous area of the brain must be targeted (Rincon et al., 2018). Therefore, developing 
effective tools is a clinical priority; for example, the use of optimized capsids that efficiently 
transduce brain cells, such as PHP.B, along with the development of novel therapeutic transgenes, 
such as antibodies that provide a high specificity and high potency. This strategy, also known as 
vectored immunoprophylaxis (VIP), has shown itself to be very stable and substrate-specific, and 
is discussed in detail in the next section. 
 
1.3 Vectored Immunoprophylaxis  
VIP consists in the passive immunization by viral vector-mediated delivery of transgenes 
encoding neutralizing antibodies into non-hematopoietic cells (Sanders and Pozio, 2017; Deal et 
al., 2015). This approach has been successfully used to treat mouse models of HIV, malaria, and 
influenza (Sanders and Pozio, 2017; Deal et al., 2014; Balazs et al., 2011; Balazs et al., 2013). 
There has been an increasing interest in passive immunization for instances, to treat Ebola virus 
using monoclonal antibodies (Sanders and Pozio, 2017). In a direct injection of monoclonal 
antibodies (mAb), to achieve a therapeutic effect, the mAb must be provided in high 
concentrations due its short lifetime, requiring multiple injections. Viral vectors allow the 
efficient and rapid delivery of the transgene, moreover, the vector can be engineered in order to 
achieve a higher tropism to a cell type or tissue (Sanders and Pozio, 2017). Hence, the delivery 
of antibodies mediated by a viral vector may lead to endogenous production and a sustained 
expression of the protein after just one injection (Sanders and Pozio, 2017). 
 
Concerning VIP therapies for CNS conditions, when produced in the peripheral muscle and 
secreted, the mAb activity in the brain was inefficient. This was probably due to the large size of 
the mAb (typically in the region of 150 kDa), the poor biodistribution of penetrating mAb 
throughout the brain parenchyma, high microglia-mediated immunogenicity (Zafir-Lavie. et al., 
2018; Bannas et al., 2017; Freskgard and Urich, 2017; Wang et al., 2016; Panza et al., 2014). 
Therefore, local production of antibodies is the most attractive option to achieve a therapeutic 
response. However, the reduced size of transgene that can be carried by a scAAV vector is 
typically much smaller than the coding sequence of a standard antibody, consequently smaller 
proteins are better suited for a scAAV-based strategy, like single-chain variable fragments (scFV) 
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or nanobodies. Typically, scFV antibodies tend to show lower affinities for their target than their 
parent templates (Niewoehner et al., 2014), considerably limiting their use as therapeutics. This 
challenge can be overcome by employing nanobodies, a technology pioneered at the Vlaams 
Instituut voor Biotechnologie (VIB) and the Vrije Universiteit Brussels (VUB).  
 
Nanobodies are constituted by a small single variable antigen binding domain, with a size of 
around 120 amino-acids and a molecular weight of about 15 kDa (Zhou et al., 2011). These 
molecules are produced by immunizing a camelid, followed by isolation of the immune cells to 
produce a library of nanobodies, that are further selected based on desired characteristics, such as 
high affinity and potency (Wagner et al., 2018). Nanobodies have some interesting features, such 
as stability, high specificity, high affinity to small antigens that are unavailable to mAbs, and the 
lack of the Fc region reduces the immunogenicity compared to standard mAbs (Hassanzadeh-
Ghassabeh et al., 2013). Moreover, nanobodies can easily be engineered by fusion to other 
proteins or to signal sequences. The drawbacks of these small molecules are rapid renal clearance 
due to its size and limited BBB permeability after systemic delivery (Steeland et al., 2016; Bannas 
et al., 2017). Unfortunately, when administered systemically in vivo, an anti-BACE1 nanobody 
showed no significant decrease in Ab content (Terryn et al., 2014). Hence, the need to produce a  
nanobody that provides anti-BACE1 activity by decreasing the Ab content and a more efficient 
delivery system arised. The delivery of a nanobody by an AAV vector in order to transduce brain 
cells efficiently and achieve high local concentrations of nanobody is promising. The small size 
of the nanobody allows it to be cloned into a scAAV plasmid, a conformation that boosts 
transgene expression of the transgene (Rincon et al., 2018) and allows long-term expression of 
the nanobody (Zafir-Lavie et al., 2018). 
 
Our work is focused on the establishment of a novel AAV-based therapy by using a specific anti-
BACE1 nanobody,  named B9, which was tested in vitro, showing decreasing levels of Ab in 
mammalian cells bearing the APPNL mutation (US8568717B2, 
https://patents.google.com/patent/US8568717B2/en). To achieve this purpose, we designed an 
ssAAV vector containing a hybrid cytomegalovirus/chicken b-actin (CBA) promoter driving the 
expression of the B9 nanobody. Additionally, the woodchuck post-trasnscriptional regulatory 
element (WPRE) was cloned into the transgene cassette together with SV0 poly-A (pA), which 
stabilizes the messenger RNA (mRNA). The nanobody is fused to an N-terminal BACE1 signal-
peptide, which potentially increases the nanobody binding to BACE1 by maximazing their 
interactions, since they would be distributed in the same pathway, and to a C-terminal c-myc tag, 
that allows in vivo detection of nanobody expression. Moreover, we attempted to boost the B9 
expression by administering a scAAV vector carrying the nanobody. Therefore we designed a 
scAAV conformation that potencially enables a faster production of the transgene compared to 
the ssAAV (Rincon et al., 2018). The main drawback of the scAAV conformation is the 
packaging capacity, which is half the capacity of the ssAAV conformation (McCarty et al., 2008). 
Therefore, to obtain a transgene inside the capacity range, we had to remove the WPRE from the 
transgene cassette. The role of the WPRE was reported to stabilize the mRNA (Sun et al., 2009; 
Wang et al., 2016).  
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2 Project Aims 
 
Ultimately, the goals of this work are: 
• The evaluation of the anti-BACE1 nanobody B9 activity using multiple murine strains 
after systemic delivery of a ssAAV-PHP-B-CBA-B9 –WPRE viral vector. 
• To compare the expresssion levels of B9 of an AAV vector with a single stranded 
transgene cassette - ssAAV-PHP.B-CBA-B9-WPRE, and an AAV vector with self-
complementary transgene cassette - scAAV-PHP.B-CBA-B9 without the WPRE 
sequence. 
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3 Materials and Methods 
 
3.1 Plasmid production and purification 
SURE2 supercompetent E. coli cells (Agilent technologies, 200152), were used for 
transformation of the plasmids pHelper, pPHP.B and pAAV-CAG-B9. The plasmids are 
ampicillin resistant. Transformations were performed accordingly to the following protocol: 50 
µl of SURE 2 cells were mixed with 2 µl of plasmid. The tube containing the cells was kept on 
ice for 30 minutes, followed by an incubation step of 30 seconds at 42ºC, before placing once 
again on ice for 2 minutes. Afterwards, the cells were grown in super optimal broth with catabolite 
(SOC) medium (New England Biotech, B9020S) at 37ºC and continuous shaking at 250 rpm for 
1 hour. 50 µl of cells were then plated on a lysogeny broth (LB) medium agar plate containing 
100 µg/ml ampicillin and left to grow overnight at 37ºC. The following morning, a single colony 
was picked and cultured in 5 ml of LB medium supplemented with 100 µg/ml ampicillin for 7 
hours at 37ºC, with continuous shaking at 250 rpm. After the incubation step, the culture was 
seeded at a 1/1000 dilution in 1 L of terrific broth (TB) or LB medium, accordingly to the expected 
copy number per host cell of each plasmid. The medium was supplemented with ampicillin at a 
concentration of 100 µg/ml. The cultures was incubated overnight at 37ºC and 250 rpm. 
Afterwards, cells are pelleted by centrifugation at 5000 g for 15 minutes (Beckman Coulter, 
Avanti J-C). Plasmid DNA was extracted with the QIAGEN Megaprep kit (12181) following the 
manufacturer’s instructions. Concentration and purity of the plasmid DNA samples was assessed 
by measuring the absorbance at 260 nm and by measuring the 260/280 nm ratio, respectively 
(Nanodrop Technologies, Rockland, Delaware, USA). Plasmid DNA samples were stored at -
20ºC. 
 
3.2 Cloning of plasmids 
In the cloning of pscAAV-CAG-B9, the plasmid was cloned by a two-step cloning strategy. The 
backbone plasmid was selected to later produce a vector with the self-complementary genome 
configuration. pscAAV-CBA-eGFP was digested with the restriction enzymes KpnI and Hind III 
(New England Biotechnology, R0142S and R0104S), to remove the CBA-eGFP sequence. 
Meanwhile the CAG promoter was isolated by digestion with the same enzymes from a pssAAV-
CAG-B9 (from Todd Golde’s lab). For the restriction digest, 500 ng of plasmid DNA were 
incubated with 0,5 ul of each restriction enzyme and 2 µl of the appropriate enzyme buffer for 3 
hours at 37ºC. The DNA fragments obtained were run in a 1% agarose gel for 40 min at 120 V to 
ensure separation of the fragments of interest. pscAAV and the CAG promoter were then isolated 
from the gel and purified with the QIAquick gel extraction kit (QIAGEN, 28704) following 
manufacturer’s instructions. 
 
The pscAAV backbone was dephosphorylated by Calf Intestinal Phosphatase (CIP, New England 
Biotech M0290), according to the manufacturer’s instructions. The backbone and the fragment of 
interest were then ligated using PCR. SURE2 cells were transformed as described above, and the 
colonies screened by PCR, with the following conditions: initial step of 2 minutes at 95ºC, and 
then 35 cycles of 15 seconds at 95ºC, 30 seconds at 54ºC and 50 seconds at 72ºC, finalized by a 
step of 5 minutes at 72ºC. The plasmid DNA of the colonies that transformed with pscAAV-CAG 
was purified with a QIAGEN Miniprep kit (27104), following the manufacturer’s instructions. 
Plasmids were verified by sequencing. 
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In a second step, the B9 nanobody with the BACE1 signal peptide and cmyc-tag was amplified 
from pssAAV-CAG-B9 using PCR. The protocol used was an initial step of 1 minute at 95ºC, 
and then 35 cycles of 15 seconds at 98ºC, 30 seconds at 60ºC and 40 seconds at 72ºC, finalized 
by a step of 5 minutes at 72ºC, using the primers (forward 3’-
TATTGTGCTGTCTCATCATTTTGGCAAAGAATTGGATCAAAGCTTGGTACCGAGCT-
5’ and reverse 3’-
GTCGAGGCTGATCAGCGAGCTCTAGTCGACGGTATCGATATCGATAAGCTGCTCGA
GGCG-5’). The backbone plasmid pscAAV-CAG was linearized using a 3 hours incubation with 
the restriction enzyme HindIII at 37ºC. The linearized backbone and the B9 fragment were later 
assembled using the NEBuilder Assembly HIFI kit (New England Biotechnology, E2621), with 
an incubation step of 15 min at 50ºC. The successful assembly of the construct was verified as 
described above. 
 
3.3 AAV production and purification 
Production of AAV vectors employed in the experiment described in this thesis was outsourced 
to ViGene Bioscience (Rockville, MD,USA). 
  
3.4 Animal procedures  
In the project, the following mouse strains were used: C57Bl/6 (Jackson Laboratory, Bar Harbor, 
ME), APPDutch, APPNL-G-F and APP/PS1.  
 
The APPDutch strain is a transgenic model that bears the Dutch mutation (APP693Q), which alters 
the processing of APP (Herzig et al., 2004). APPDutch mice develop a form of cerebral amyloid 
angiopathy (CAA), with a phenotype characterized by severe hemorrhages and amyloid 
deposition in the cerebral vessels (Timmers et al., 1990). There are no plaques formation in this 
strain and CAA develops at 22-24 months of age (Herzig et al., 2004). The APPNL-G-F is a knock-
in model that bears 3 mutations: APP KM670/671 NL (Swedish), APP I716 F (Iberian) and APP 
E693G (Artic) (Sakakibara et al., 2018). Each mutation has an effect on the properties of Ab 
production, deposition and toxicity: the swedish mutation increases the Ab production, the iberian 
one increases the ratio Ab42/Ab40, and the artic mutation promotes the Ab aggregation 
(Sakakibara et al., 2018). This model is characterized by aggressive amyloidosis, and Ab 
deposition at early stages (Saito et al., 2014). APP/PS1is a transgenic model bearing the APP 
KM670/671 NL mutation, and the PSEN1 L166P mutation. The expression of transgene APP is 
3-fold higher than the endogenous APP, and a high ratio of Ab42/40. This model is characterized 
by an aggressive amyloidosis, and plaque formation in the cortex at 6 weeks of age and 3-4 
months in the hippocampus (Radde et al., 2006).  
 
The mice have been employed to test the efficacy of the therapeutic nanobody by reducing the 
amyloid load. The vector was administered via tail vein with a dose of 1x1012 vector genome 
(vg)/mice (total volume of 100 µl) of each AAV vector. The injection of APPDutch mice was 
performed at 13 weeks of age. The analysis of brain samples was performed 4 weeks after 
injection. The APPNL-G-F mice received the vector at 6 or 16 weeks of age. The analysis of brain 
samples was performed at 18 or 21 weeks of age, accordingly. The APP/PS1 mice were 
administered at the age of 6 weeks. The analysis of brain samples was performed 16 weeks of 
age.  
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For the experiment of comparison between the ssAAV-CBA-B9-WPRE vector and the novel 
scAAV-CBA-B9 vector, APPDucth mice were used. The vector was administered via tail vein with 
a dose of 1x1012 vg/mice (total volume of 100 µl) of each AAV vector. The injection of the 
APPDutch was performed at 6 weeks old. The analysis of brain samples was performed 4 weeks 
after injection. The C57Bl76, untreated, have been employed only to provide a baseline of protein 
expression for the Mass Spectrometer analysis. Therefore, they were sacrificed at the age of 10 
weeks to age-match the groups treated with the vector. Before harvesting the brain samples, all 
the animals were injected intra-peritoneally (IP) with Dolethal (Vetoquinol, UK) to induce 
sedation. The mice were then transcardially perfused with ice-cold phosphate buffered saline 
(PBS). The brain was collected, and the right hemisphere was post-fixated in 4% 
paraformaldehyde (PFA) overnight. 50 µm brain sections were obtained by a vibrating microtome 
(LEICA VT1000S). The left hemisphere was dissected to isolate the cortex, the hippocampus, 
and the midbrain regions. The samples were snap-frozen separately in liquid nitrogen and stored 
at -80ºC until further processing. 
 
3.5 Extraction of soluble and insoluble protein  
In order to later quantify the content of Ab peptides in the different brain regions, extraction of 
the soluble and insoluble fractions of Ab is performed. 
 
For the soluble fraction, around 35 mg of cortex tissue or the whole hippocampus are 
homogenized, in FastPrep tubes (Lysing Matrix D, MP Biomedical,  
(MP116913050) after addition of an extraction buffer. The buffer composition is 10 ml of Tissue 
protein extraction reagent (T-PER, PIERCE, 78510), 1 tablet complete mini protease inhibitor 
(PI, Roche, 11836153001), 100 µl of Phosphatase inhibitor cocktail 2 (Sigma-Aldridge, P5726-
1ML) and 100 µl of Phosphatase inhibitor cocktail 3 (Sigma-Aldridge, P0044-1ML). The buffer 
is added to the tube, 10x the equivalent volume based on tissue weight. The samples are then 
homogenized for 45 sec 6.5 m/s, using a MP Fastprep-24 tissue and cell homogenizer. The 
homogenized samples were spun down for 5 min, 5000 g at 4ºC, and the supernatant transferred 
to Beckman ultracentrifugation tubes. Samples were centrifuged for 1 hour, at 4ºC and 131440 g 
(Beckman Ultra Optima TLX). The supernatant (soluble fraction) was collected and transferred 
to a new tube. Both the supernatant and the pellet, later used to obtain the insoluble fraction, are 
stored at -80ºC. 
 
For the insoluble fraction, the aforementioned pellet is resuspended in 6M GuHCl (ThermoFisher, 
24110) with PI, 2x equivalent volume based on the pellet weight, and then sonicated for 30 
seconds, 10% amplitude, using a Branson Digital sonifier. After sonication, samples are vortexed 
and incubated for 1 hour at 25ºC. At the end of the incubation step, the supernatant is transferred 
into screw-cap tubes (Starstedt) and centrifuged for 20 minutes, at 4ºC and 212911 g. The 
supernatant is then collected and diluted 12x in GuHCl diluent buffer (20 mM phosphate, 0,4 M 
NaCl, 2mM EDTA, 0,05%(w/v) NaN3 and 0,075%(w/v) 3-[(3-Cholamidopropyl) 
dimethylammonio]-1-propanesulfonate (CHAPS) 
 
3.6 Protein determination 
To ensure that the same total amount of protein per each sample is loaded on the ELISA plate, 
protein content is measured based on the methods previously described (Lowry et al., 1951; 
Peterson et al., 1977). In summary, the total amount of protein in the sample is determined by 
using a standard curve of known concentrations of bovine serum albumin (BSA, ThermoFisher). 
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To allow protein precipitation, 100 µl of 0,15%(w/v) deoxycholate (DOC) (Thermo Scientific) 
and 100 µl of 72% trichloroacetic acid (TCA) (Thermo Scientific are added to the samples and 
the BSA standards (1ml final volume). Samples are carefully vortexed and incubated for 10 
minutes on ice. After the incubation, samples are centrifugated for 10 minutes, 4ºC and 16200 g 
in a Heraeus Fresco 21 Microcentrifuge. Afterwards, the supernatant is gently aspired and the 
pellet resuspended in 250 µl ddH2O and 750 µl of a solution containing Na2CO3, NaOH, Na2-
Tartratex2H20, SDS, CuSO4x5H20, and incubated at room temperature for 30 minutes. Then, 75 
µl of Folin-Ciocalteus-Phenol-Reagent (Merck 9001) was added, immediately mixed and 
incubated for 45 minutes at room temperature. The absorbance was measured at 750 nm in a 
spectrophometer (Thermo-Scientific). 
 
3.7 Quantification Ab peptides  
The Ab peptides were measured by performing a sandwich ELISA assay with the following 
protocol. Nunc maxisorp flat-bottom 96 wells plates (ThermoScientific, 44-2404-21) were coated 
with coating buffer (10 mM Tris-HCl, 10 mM NaCl, 10 mM NAN3) supplemented with the 
capture antibody against human Ab40 (JRF/cAbeta40/28) or Ab42 (JRF/cAbeta42/26) provided 
by Janssen, at a final concentration of 1,5 µg/ml. The plates are incubated overnight at 4ºC on a 
tilting table. 
 
 The next morning, the coating buffer is discarded by quickly inverting the plate, and the wells 
were rinsed 5 times with 150 µl of PBS (Gibco) supplemented with 0,05% Tween20 (Sigma-
Aldridge). The plates were blocked with PBS with 0,1% casein (PBS-casein, Sigma-Aldridge), 
and incubated at room temperature for 4 hours. To ensure that the same amount of total protein is 
loaded on the coated plate for all of the samples, they were diluted in PBS-casein to a standard 
concentration of 3 µg/µl for cortex, and 1,5 µg/µl for hippocampus. The samples were further 
diluted, depending on the strain, in order to ensure that the absorbance was inside the linear range 
of the standard curve.  
 
After preparation of the appropriate dilutions, 30 µl of conjugated antibody huAB25-HRPO 
(Janssen), diluted at the concentration of 1/6000 in PBS-casein, were pipetted per well into a 96 
wells PCR plate, non-skirted (VWR, 732-2879). Then, 30 µl of each sample dilution were added 
per well and mixed carefully with the conjugated antibody by pipetting up and down. When all 
the samples were loaded, dilutions at a known concentration of the appropriate Ab peptide were 
prepared as a standard curve and loaded in the PCR plate. The content of the plate was mixed on 
a plate shaker for 5 minutes at 1000 rpm. To ensure that the full content of the plate was at the 
bottom of each well, a centrifugation step of 5 minutes, 1000 rpm was performed. 30 µl of each 
well were then loaded in the coated Nunc maxisorp plate, and incubated overnight at 4ºC on a 
tilting table. 
 
The following morning, the sample-antibody mix were discarded, and the wells were rinsed 5 
times with PBS supplemented with 0,05% Tween20. During the last wash, the developing 
solution containing 6 ml of 100mM NaAc (Sigma Aldrich ) pH4.9, 60 µl of 3,3′,5,5′-
Tetramethylbenzidine (TMB, Sigma Aldrich) and 6 µl of 30% H2O2 (Sigma Aldrich) was 
prepared. 50 µl of developing solution was pipetted in each well. The plate was then incubated 
for 8-10 minutes in the dark.  
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After the incubation, 2N H2SO4 was added to stop the colorimetric reaction, and the absorbance 
measured at 450 nm in a Perkin Elmer EnVision 2103 Multilabel reader. 
 
3.8 Immunohistochemistry  
50 µm thick sagittal brain sections were washed for 10 minutes with Tris buffered saline (TBS) 
(50 mM Tris-Cl, 150 mM NaCl mM, pH 7.6) in a 24 well plate (VWR). 500 µl of the blocking 
solution containing 1% Triton X-100 in TBS with 10% normal donkey serum (NBS) (Abcam) 
were added to each well and the plate is stored at room temperature for 1 hour on a tilting table. 
The primary antibodies (Rabbit anti-cMyc tag to produced by Sigma-Aldrich #C3956, to identify 
the nanobody, diluted 1:500; Guinea pig anti-Neun, Sigma-Aldrich #ABN90, diluted 1:400) were 
diluted in the blocking solution. 500 µl of the primary solution are added to each well. The plate 
were stored overnight at 4ºC on a tilting table. The following morning, the brain sections were 
washed with TBS 3 times and incubated with 500 µl/well of the secondary antibody solution 
(Donkey anti-guinea pig Cy5, Jackson Immuno #706-175-148; Donkey anti-rabbit Alexa488, 
Invitrogen #A21206, added to the blocking solution at a dilution of 1:200 and 1:500 respectively). 
The plate was incubated for 1 hour at room temperature on a tilting table. Sections are then rinsed 
with TBS and mounted with Fluromount-G containing with DAPI (Thermo Scientific, 4959-52). 
The sections were imaged with a Leica DM5500 epifluorescence microscope with the objectives 
APO5x/0.07 and APO2.5x/0.15. 
 
3.9 Shotgun LC-MS/MS  
The following brain regions were sent to the VIB Proteomics Core to be analysed: Right cortex 
of C57Bl6 noninjected, and C57Bl6/APPDutch injected with ssAAV-PHP.B-CAG-B9-WPRE and 
scAAV-PHP.B-CAG-B9. Tissue samples were processed with the iST kit (PreOmics, Germany, 
P.O.00001). The B9 expression was measured by liquid chromatography coupled to mass-
spectometry in tandem (LC-MS/MS). LC-MS/MS runs on all 9 samples were searched together 
using the MaxQuant algorithm (version 1.6.3.4) with default search settings including a false 
discovery rate set at 1% on both the peptide and protein level. 
 
3.10 Statistical analysis  
Differences in Ab concentration between the brain regions were determined using an unpaired t-
test with Welch’s correction. All statistical analysis was performed using GraphPad (San Diego, 
CA,USA). 
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4 Results  
 
4.1 Evaluation of the nanobody activity in APPDutch mice 
Anti-BACE1 nanobody (B9) activity was assessed by measuring the concentration of Ab content 
post-injection on APPDutch mice. Two groups of mice were injected either with the ssAAV-PHP.B-
CBA-eGFP-WPRE (control vector) or ssAAV-PHP.B-B9. This model is characterized by a high 
ratio of Ab40/Ab42 (Herzig et al., 2004). Hence, only the Ab40 fractions were measured in this 
assay. The animals were injected with a dose of 1x1012 vg/mice of vector through tail vein 
injection at 13 weeks of age and euthanized 4 weeks post-injection. The Ab levels were measured 
by sandwich ELISA on the regions of interest, the cortex and the hippocampus, on both soluble 
and insoluble fraction. 
 
An evident decrease in Ab40 species post-delivery of the vector was detected in the soluble 
fractions, especially from the hippocampus region (Fig. 2a-b). In the insoluble fraction, a 
statistically significant decrease in the Ab40 species was measured in samples obtained from the 
hippocampus, but not from the cortex (Fig. 2c-d).  
 
Figure 2. Decrease in Ab species post-injection of ssAAV-PHP.B-CBA-B9 in APPDutch. Mice were injected with 
ssAAV-PHP.B-CBA-eGFP-WPRE and ssAAV-PHP.B-CBA-B9-WPRE at a dose of 1x1012 vg/mice. The Ab content 
in the fractions of interest was measured. a) Soluble Ab40 from cortex; b) Soluble Ab40 from hippocampus, c) 
Insoluble Ab40 from cortex, d) Insoluble Ab40 from hippocampus. (n=4 per group) * p<0.05, ** p<0.005 
Despite the promising results in APPDutch, this model does not develop cognitive changes or show 
plaque aggregation, which limits the potential readouts (behavioral and physiological) that can be 
used to assess the effect of B9 delivery. Therefore, we decided to assess the therapeutic efficacy 
of B9 in AD mouse models such as APPNL-G-F and APP/PS1. 
 
4.2 Evaluation of the nanobody activity in APPNL-G-F  
The assessment of the efficacy of B9 in different mouse models allowed to test the efficiency of 
this therapy across strains. Firstly, we assessed the efficiency of B9 in lowering Ab levels in 
APPNL-G-F. The Ab levels were measured in two mouse groups injected with either ssAAV-
PHP.B-CBA-eGFP-WPRE or ssAAV-PHP.B-B9, at a dose of 1x1012 vg/mouse. Injections were 
performed at 16 weeks old and mice were euthanized at 21 weeks of age. The Ab content was 
measured by a sandwich ELISA, on the soluble fraction of Ab40, obtained from cortex and 
hippocampus, and soluble Ab42 fractions from the cortex region. The insoluble Ab40 fractions 
from cortex and hippocampus regions, and soluble Ab42 fraction from the hippocampus regions 
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are not represented due to low levels of Ab in the fractions. A statistically significant decrease 
was detected in the soluble Ab42 fraction obtained from cortex region following B9 
administration. Moreover, analysis of the insoluble Ab42 fractions showed no decrease, but there 
was a decreasing trend content on the soluble Ab40 fractions (Fig. 3a-e).  
 
 
Figure 3. Ab species did not decrease post-injection of ssAAV-PHP.B-CBA-B9 in APPNL-G-F. Mice were injected 
with ssAAV-PHP.B-CBA-eGFP-WPRE and ssAAV-PHP.B-CBA-B9-WPRE with 1x1012 vg/mice. The Ab content in 
the fractions of interest was measured. a) Insoluble Ab42 fraction of the cortex; b) Insoluble Ab42 fraction of the 
hippocampus, c) Soluble Ab42 fraction of the cortex, d) Soluble Ab40 fraction of the cortex, e) Soluble Ab40 fraction 
of the hippocampus. (n=4 per group) * p<0.05 
The levels of Ab in the majority showed no statistically significant decrease in the analyzed 
samples, possibly due to the accumulation of Ab deposits, that at age of analysis (16 weeks) in 
APPNL-G-F, is already established. Therefore, the injection of mice at younger age, in which there 
are lower accumulation of Ab deposits could unravel a therapeutic window. 
 
4.3 Evaluation of the nanobody activity at younger age in APPNL-G-F 
To investigate whether age plays a role in the effect seen after B9 administration, Ab levels were 
measured in two groups of mice injected at 6 weeks of age either with ssAAV-PHP.B-CBA-
eGFP-WPRE or ssAAV-PHP.B-B9 (10x1012 vg/mouse). Mice were euthanized at 18 weeks of 
age. The Ab content was measured by a sandwich ELISA, as before, insoluble fractions from 
cortex and hippocampus regions on both Ab40 and Ab42 species, and soluble Ab42 fraction from 
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the cortex region. The remaining soluble fractions are not represented since the low Ab levels on 
these fractions. 
 
As expected, a statistically significant decrease in Ab levels was detected in the insoluble Ab40 
fractions extracted from the hippocampus and cortex, as well as in the insoluble Ab42 fraction 
obtained from the hippocampus region, which is the main constituent of the Ab plaques (Fig. 4a-
c). The insoluble and soluble Ab42 fractions obtained from the cortex showed a minor decrease 
in Ab levels, which could be due to the lower levels of Ab present in the fraction (Fig. 4d-e). 
Nonetheless, a decreasing trend was observed in the majority of the fractions which led us to 
conclude that the B9 activity is sufficient to achieve a decrease in Ab levels.  
 
 
Figure 4. Ab species showed a decrease post-injection of ssAAV-PHP.B-CBA-B9 in APPNL-G-F. Mice were injected 
with ssAAV-PHP.B-CBA-eGFP-WPRE and ssAAV-PHP.B-CBA-B9-WPRE at a dose of 1x1012 vg/mouse. The Ab 
content in the fractions of interest was measured. A) Insoluble Ab40 from the cortex; b) Insoluble Ab40 fraction from 
the hippocampus, c) Insoluble Ab42 fraction from the hippocampus, d) Insoluble Ab42 fraction from the cortex, e) 
Soluble Ab42 fraction from the cortex. (n=4 per group) * p<0.05, ** p<0.005 
 
4.4 Evaluation of the nanobody activity in APP/PS1  
The APPNL-G-F strain is still being characterized, and there are contradictory results regarding 
behavioral changes in the strain (Latif-Hernandez et al., 2019). Meanwhile, if Ab is reduced after 
injecting the vector, it would be expected to decrease the disease severity, which would manifest 
itself in behavioral testing. Therefore, we tested the efficiency of B9 in a the APP/PS1 model, 
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which has a known behavioral phenotypes (e.g. Morris Water Maze and passive avoidance) 
(Radde et al., 2006).  
 
Due to the high severity of amyloidosis in this strain, mice were immediately injected at a young 
age (6 weeks), in order to measure Ab levels before the plateau levels of deposit is achieved. Ab 
levels were measured in two injected groups: one was injected with ssAAV-PHP.B-CBA-eGFP-
WPRE and a second injected with ssAAV-PHP.B-B9. The dose used was 1x1012 vg/mouse. Mice 
were injected at 6 weeks of age, and euthanized 10 weeks later. The Ab content was measured as 
previously described, insoluble fractions from cortex and hippocampus regions on both Ab40 and 
Ab42 species, as well as in the soluble Ab42 from cortex and hippocampus regions. The 
represented fractions are the ones where the levels of Ab were measurable. Unfortunately, there 
was no significant decrease observed in any fraction (Fig. 5a-f).  
  
Figure 5. Ab species in the APP/PS1 were not reduced by treatment with ssAAV-PHP.B-CBA-B9. Mice were 
injected with ssAAV-PHP.B-CBA-eGFP-WPRE or ssAAV-PHP.B-CBA-B9-WPRE at a dose of 1x1012 vg/mouse. 
The Ab content in the fractions of interest was measured. a) Insoluble Ab42 fraction from cortex; b) Insoluble Ab42 
fraction from hippocampus, c) Insoluble Ab40 fraction from cortex, d) Insoluble Ab40 fraction from hippocampus, e) 
Soluble Ab42 fraction from cortex, f) Soluble Ab42 fraction from hippocampus. (n=4 per group) 
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4.5 Comparison of scAAV-PHP.B-CBA-B9 and ssAAV-PHP.B-CBA-B9 
The lack of B9 efficiency may be due to the insufficient production of the nanobody comparing 
the high levels of production of the Ab peptides. Therefore, we attempted to boost the B9 
expression by administering a scAAV vector carrying the nanobody.  
 
For this experiment, APPDutch mice were used, since B9 was shown to reduce Ab in this mice 
strain under specific conditions (see Fig. 2). Due to time constraints, however, mice were injected 
at a younger age int his set of experiment, although the time between injection and euthanasia 
was kept constant. The concentration of Ab species was measured in 3 injected groups – a group 
injected with ssAAV-PHP.B-B9-WPRE, a group of scAAV-PHP.B-B9, and the control group 
injected with ssAAV-PHP.B-eGFP Each mouse received a dose of 10x1012 vg at 6 weeks of age 
and were sacrificed 4 weeks later.  
 
The Ab content was measured by a sandwich ELISA, as previously described, on soluble Ab40 
and soluble Ab42 fractions of the cortex and hippocampus regions, since only these fractions 
levels of Ab in the detection range. In this assay, no statistically decrease was observed between 
the groups (Fig. 6a-d), possibly due to the low concentration of Ab species present in the regions 
of interest at the age of analysis. However, a clear trend in decreasing content in the group injected 
with the ssAAV-PHP.B-CBA-B9-WPRE compared to the control group on the fractions from the 
hippocampus region. 
 
 
 
Figure 6. Ab species did not decrease post-injection of ssAAV-PHP.B-CBA-B9-WPRE or scAAV-PHP.B-CBA-
B9 in APPDutch. Mice were injected with ssAAV-PHP.B-CBA-eGFP-WPRE, ssAAV-PHP.B-CBA-B9-WPRE, 
scAAV-PHP.B-CBA-B9 with 1x1012 vg/mice. The Ab content in the fractions of interest was measured. a) Soluble 
Ab40 fraction of the cortex; b) Soluble Ab40 fraction of the hippocampus, c) Soluble Ab42 fraction of the cortex, d) 
Soluble Ab42 fraction of the hippocampus. (n=4 per group) 
To evaluate the B9 distribuition after injection with the vectors ssAAV-CBA-B9-WPRE and 
scAAV-CBA-B9, brain sections were stained against the c-myc tag to compare the B9 distribution 
in hippocampus and cortex when a ssAAV vector or a scAAV vector was used (Fig. 7). The 
expression of B9 in the sections of mice injected with the ssAAV vector was widespread (Fig. 
7a). Unexpectedly, in the sections taken from mice injected with the scAAV vector, B9 expression 
was limited to the hippocampus (Fig. 7b). 
 
Furthermore, we performed a LC-MS/MS shotgun analysis of the proteome on samples from the 
cortex, to assess the relative amounts of B9 expression between mice injected with scAAV-CBA-
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B9 and those injected with ssAAV-CBA-B9-WPRE. To establish which proteins were 
upregulated or downregulated, C57Bl/6 non-injected mice were used as a control. This approach 
allows a relative quantification and identification of proteins present in the sample, quantifying 
the fold-change between different conditions.  
 
Mice injected with scAAV-CBA-B9 were expected to have a higher expression of the nanobody 
compared to those injected with ssAAV-CBA-B9-WPRE. Even though the nanobody was 
detected in the samples obtained from mice injected with scAAV-CBA-B9, there was no 
overexpression of B9 detected (Fig. 8a), which corroborates the results of the staining 
experiments. In the samples from mice injected with ssAAV-CBA-B9-WPRE there was a 
statistically significant overexpression of the nanobody, compared to controls (Fig. 8b), as well 
as in comparison to samples from mice injected with scAAV-CBA-B9 (Fig. 8c). 
 
Figure 7. Differences in B9 distribution post-injection with ssAAV-CBA-B9-WPRE and scAAV-CBA-B9. 
Costaining of specific marker for neurons (NeuN, magenta) and marker for B9 (c-myc-tag, green). White arrows 
indicate B9 distribution on hippocampus region; yellow arrows indicate B9 distribution on cortex. a) Representative 
images from cortex and hippocampus regions systemically injected with ssAAV-CBA-B9-WPRE, objective APO5x. 
Scale bar: 50µm. b) Representative images from cortex and hippocampus regions systemically injected with scAAV-
CBA-B9, objective APO2.5x. Scale bar: 100µm. 
NeuN C-myc tag Merge 
a) 
NeuN C-myc tag Merge 
b) 
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Figure 8. B9 is overexpressed only in the ssAAV-CBA-B9-WPRE injected mice. Volcano plot of shotgun 
proteomics: a) scAAV-CBA-B9 and C57Bl/6 samples pairwise comparison, b) ssAV-CBA-B9-WPRE and C57Bl/6 
samples pairwise comparison , c) ssAAV-CBA-B9-WPRE and scAAV-CBA-B9 samples pairwise comparison. FDR 
= 0.05, S0 = 1 
 
 
 
 
a) b) 
c) 
Ctrl scAAV Ctrl ssAAV 
ssAAV scAAV 
  24 
5 Discussion  
In gene therapy for CNS disorders, the delivery and expression of the transgene are the main 
concerns in the field (Deverman et al., 2016). In AD specifically, the main concern is the 
production of an efficient therapeutic molecule that halts the progression of the disease (Peng et 
al., 2016; Heppner et al, 2015). AAV-based therapy emerges as an interesting mechanism to 
deliver the therapeutic a transgene, for instances encoding a potent nanobody with an anti-BACE1 
activity, which is a promising novel therapy. 
  
The anti-BACE1 activity of the nanobody B9 was previously validated in vitro (Rincon et al., 
unpublished). The administration of the nanobody decreased the activity of BACE1 without 
affecting the protein levels, however changes in Ab levels were observed (US8568717B2, 
https://patents.google.com/patent/US8568717B2/en). In order to validate the activity of the 
nanobody in vivo, the Ab species were measured. Despite not being a direct quantification of the 
nanobody, it is possible to extrapolate the anti-BACE1 activity of the nanobody, since there are 
changes in the Ab content between the control injected group and the group injected with the 
vector containing the nanobody. The main focus of the measurements of Ab40 and Ab42 was the 
insoluble fraction since it has an important role in the onset of the disease (Wang et al., 1999), 
therefore major changes in these fractions are relevant for validation and efficiency of the therapy. 
Moreover, the Ab42 fractions were also considered relevant to the AD model strains, since this 
peptide is more prone to aggregate and form the amyloid plaques, an hallmark of AD (Jankowsky 
and Zheng, 2017). 
  
The efficiency of B9 in decreasing Ab species was tested in multiple strains, since the therapeutic 
response may vary between them. APPDutch strain is characterized for the high ratio of Ab40/42, 
and accumulates Ab principally around the cerebral vasculature (Herzig et al., 2004). 
Parenchymal amyloid plaques, typical of AD in patients, are not observed. Therefore, we 
measured the changes of Ab content post-injection with the vector bearing the nanobody in two 
alternative AD models, APPNL-G-F and APP/PS1, which both show deposition of parenchymal 
plaques.  
 
The decrease of Ab species in APPDutch mice and APPNL-G-F mice allowed the conclusion that B9 
has anti-BACE1 activity in vivo, even though in APP/PS1 the results did not show any statistically 
significant decrease of Ab peptides. This is possibly due to the severity of the model and rapid 
accumulation of Ab (Radde et al., 2006). However, validation of B9 activity in this murine model, 
if possible, would open the door for behavior tests, which would demonstrate a link between 
decreased Ab load and improved cognition.  
 
In order to validate B9 in APP/PS1, an optimized therapeutic window must be determined which 
allows changes in Ab levels to be measured post vector administration. There is a clear age-
dependent factor in the activity of B9, which could be related to the severity of the amyloidosis 
in each model (Radde et al., 2006). The generation of Ab peptides follows a sigmoid curve, if the 
B9 is administered when the levels of Ab are in the exponential phase, it is easier to measure the 
difference in the levels of production than when the system is already in the plateau phase and 
saturated of Ab species (Kumar and Walter, 2011), Therefore, the decrease of the peptide is not 
measurable, and the therapeutic effect of the nanobody is neglectable. An alternative to this 
approach is to boost the expression of the nanobody, it was expected that a higher expression of 
the nanobody to have an increase the impact on the levels of Ab species. 
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To test if a scAAV without the regulatory elements would actually boost the expression of B9, a 
scAAV-CBA-B9 vector was produced and injected in the already validated APPDutch mice. As a 
control, the ssAAV-CBA-B9-WPRE was used, thus comparing this conformation and the 
scAAV-CBA-B9. The scAAV conformation is reported to increase the transgene expression and 
to have a “ready-to” transcribe conformation, compared to the ssAAV (Rincon et al., 2018). The 
major drawback of the scAAV vector is the packaging capacity, compromising about half of the 
transgene size compared to ssAAV conformation (McCarty et al., 2008). Therefore, in the 
scAAV-CBA-B9, the WPRE had to be removed, although the WPRE was reported to have a role 
in stabilizing the mRNA, allowing more efficient transgene expression (Sun et al., 2009; Wang et 
al., 2016). In mice injected with the scAAV vector, we expected B9 expression would be higher, 
and consequently changes in Ab levels would be more pronounced, when compared to mice 
injected with ssAAV. However, the Ab content measured was equivalent in both groups. 
However, it should be noted that there was also no change in the Ab content between control and 
B9 injected mice, which may be related to the fact that very young mice were used, in which 
amyloid levels were much lower than usually assayed. Furthermore, we assessed the impact of 
genome configuration on nanobody expression using LC-MS/MS, in which samples from mice 
injected with ssAAV-CBA-B9-WPRE showed higher B9 expression compared with those 
injected with scAAV-CBA-B9, corroborating the results from our immunohistochemistry 
experiments. Therefore, we concluded that even though the scAAV conformation could 
potencially provide a boost in transgene expression, the whole ssAAV trangene cassette proved 
to be more efficient in the expression of the B9, showing the importance of the regulatory 
elements in the expression of a transgene. 
  
In follow up experiments, in order to have a more accurate comparison for the efficiency between 
the ssAAV conformation and the scAAV conformation, a group has to be added, a ssAAV-CBA-
B9 without the WPRE, to put in evidence the role of WPRE in the efficiency of the delivery of 
the vector, and expression of the transgene. Due to time constraints and lack of mice to fulfill a 
group, we were unable to implement a group of mice injected with the vector. Therefore, to 
progress with the experiment it is required that a group of mice at the already validated age of 
injection/analysis is injected with the previously injected vectors and ssAAV-CBA-B9 without 
the WPRE.  
 
Nevertheless, this novel AAV-based nanobody delivery platform shows promise for the treatment 
of AD. Further improvements to the system, such as boosting transgene expression, and may lead 
to a more pronounced therapeutic effect. Finally, the base technology can be expanded and used 
to target other proteins implicated in various CNS disorders, for which there are currently limited 
treatment options, promising a revolution in how we approach the treatment of these conditions. 
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